Asahi Kasei Pharma America (AKP America) is a biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients throughout the world. The company is a wholly-owned subsidiary of Asahi Kasei Pharma, Corp.
ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), our lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. This drug has successfully completed a Phase 2b clinical trial in disseminated intravascular coagulation (DIC) and Phase 3 trial is currently underway. This product might also be beneficial for a number of other indications.